Silvano Cella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/901722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Role of Aspartate Transaminase to Platelet Ratio Index (APRI) for the Prediction of Non-Alcoholic Fatty Liver Disease (NAFLD) in Severely Obese Children and Adolescents. Metabolites, 2022, 12, 155.	1.3	11
2	COVID-19 vaccine hesitancy among undocumented migrants during the early phase of the vaccination campaign: a multicentric cross-sectional study. BMJ Open, 2022, 12, e056591.	0.8	25
3	Ethnic, clinical, and pharmacological predictors of high social dependence in COVID-19 patients admitted to post-acute care. Journal of Public Health Research, 2022, 11, 227990362211041.	0.5	0
4	Risk factors, awareness of disease and use of medications in a deprived population: differences between indigent natives and undocumented migrants in Italy. Journal of Public Health, 2021, 43, 302-307.	1.0	4
5	The Age-Dependent Increase of Metabolic Syndrome Requires More Extensive and Aggressive Non-Pharmacological and Pharmacological Interventions: A Cross-Sectional Study in an Italian Cohort of Obese Women. International Journal of Endocrinology, 2021, 2021, 1-10.	0.6	4
6	Frequent Medical Supervision Increases the Effectiveness of a Longitudinal Multidisciplinary Body Weight Reduction Program: A Real-World Experience in a Population of Children and Adolescents with Obesity. Nutrients, 2021, 13, 3362.	1.7	5
7	Multi-centric assessment of COVID-19 immunization access and demand among undocumented migrants. European Journal of Public Health, 2021, 31, .	0.1	0
8	Effects of an acute bout of exercise on circulating extracellular vesicles: tissue-, sex-, and BMI-related differences. International Journal of Obesity, 2020, 44, 1108-1118.	1.6	60
9	Will undocumented migrants contribute to change epidemiology, presentation and pharmacologic treatment of diabetes in Western countries?. Primary Care Diabetes, 2020, 14, 21-28.	0.9	3
10	Evaluation of an Amino Acid Mix on the Secretion of Gastrointestinal Peptides, Glucometabolic Homeostasis, and Appetite in Obese Adolescents Administered with a Fixed-Dose or ad Libitum Meal. Journal of Clinical Medicine, 2020, 9, 3054.	1.0	4
11	The Appetiteâ^'Suppressant and GLP-1-Stimulating Effects of Whey Proteins in Obese Subjects are Associated with Increased Circulating Levels of Specific Amino Acids. Nutrients, 2020, 12, 775.	1.7	18
12	Impact of a Three-Week in-Hospital Multidisciplinary Body Weight Reduction Program on Body Composition, Muscle Performance and Fatigue in a Pediatric Obese Population with or without Metabolic Syndrome. Nutrients, 2020, 12, 208.	1.7	19
13	Effects of a 3-Week In-Hospital Body Weight Reduction Program on Cardiovascular Risk Factors, Muscle Performance, and Fatigue: A Retrospective Study in a Population of Obese Adults with or without Metabolic Syndrome. Nutrients, 2020, 12, 1495.	1.7	16
14	Undocumented migrants during the Covid-19 pandemic: social conditions, clinical features and pharmacological treatment. Journal of Public Health Research, 2020, 9, 1852.	0.5	10
15	Whey Proteins Reduce Appetite, Stimulate Anorexigenic Gastrointestinal Peptides and Improve Glucometabolic Homeostasis in Young Obese Women. Nutrients, 2019, 11, 247.	1.7	21
16	Multidisciplinary Integrated Metabolic Rehabilitation in Elderly Obese Patients: Effects on Cardiovascular Risk Factors, Fatigue and Muscle Performance. Nutrients, 2019, 11, 1240.	1.7	12
17	Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides. Nutrition Research, 2018, 52, 71-79.	1.3	32
18	GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome. Growth Hormone and IGF Research, 2018, 39, 13-18.	0.5	3

#	Article	IF	CITATIONS
19	Gender and age related differences in the use of medicines for chronic diseases among undocumented migrants. International Journal of Migration, Health and Social Care, 2018, 14, 221-229.	0.2	3
20	Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases. Pulmonary Pharmacology and Therapeutics, 2018, 53, 80-85.	1.1	16
21	Psychotropic drugs prescription in undocumented migrants and indigent natives in Italy. International Clinical Psychopharmacology, 2017, 32, 294-297.	0.9	5
22	Drugs Delivery by Charities: A Possible Epidemiologic Indicator in Children of Undocumented Migrants. Journal of Immigrant and Minority Health, 2017, 19, 1379-1385.	0.8	0
23	Pharmacoepidemiological data from drug dispensing charities as a measure of health patterns in a population not assisted by the Italian National Health Service. Journal of Public Health Research, 2016, 5, 623.	0.5	2
24	The burden of chronic noncommunicable diseases in undocumented migrants: a 1-year survey of drugs dispensation by a non–governmental organization in Italy. Public Health, 2016, 141, 26-31.	1.4	21
25	Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. Food and Nutrition Research, 2015, 59, 29678.	1.2	36
26	Different Effects of Cholestyramine on Postprandial Secretions of Cholecystokinin and Peptide YY in Women with Bulimia Nervosa. Neuropsychobiology, 2014, 70, 228-234.	0.9	9
27	Health needs assessment in patients assisted by a pharmaceutical non-profit charitable organisation: a preliminary pharmacoepidemiological survey based on the analysis of drug dispensation within Italy's Banco Farmaceutico. Italian Journal of Medicine, 2013, 9, .	0.2	0
28	Effect of a somatostatin infusion on circulating levels of adipokines in obese women. Metabolism: Clinical and Experimental, 2012, 61, 1797-1802.	1.5	4
29	Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity. European Journal of Endocrinology, 2011, 165, 421-427.	1.9	16
30	Children with Prader–Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. European Journal of Endocrinology, 2010, 162, 499-505.	1.9	56
31	Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes. European Journal of Endocrinology, 2009, 160, 753-758.	1.9	8
32	Menopausal transition: A possible risk factor for brain pathologic events. Neurobiology of Aging, 2009, 30, 71-80.	1.5	31
33	The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2007, 28, 515-518.	1.5	21
34	Pilot Study of the Efficacy and Safety of a Modified-Release Magnesium 250mg Tablet (Sincromag??) for the Treatment of Premenstrual Syndrome. Clinical Drug Investigation, 2007, 27, 51-58.	1.1	19
35	Testosterone Inhibition of Growth Hormone Release Stimulated by a Growth Hormone Secretagogue. Neuroendocrinology, 2006, 84, 115-122.	1.2	5
36	Growth hormone abuse: methods of detection. Trends in Endocrinology and Metabolism, 2005, 16, 160-166.	3.1	32

#	Article	IF	CITATIONS
37	The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat. Neurobiology of Aging, 2005, 26, 259-264.	1.5	49
38	Abuse of Recombinant Human Growth Hormone: Studies in Two Different Dog Models. Neuroendocrinology, 2004, 79, 237-246.	1.2	6
39	Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clinical Endocrinology, 2004, 61, 487-493.	1.2	24
40	The 5-HT1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Research, 2003, 983, 215-222.	1.1	58
41	Molsidomine antagonizes L-NAME-induced acquisition deficits in a recognition memory task in the rat. Pharmacological Research, 2003, 47, 311-315.	3.1	19
42	The GABAB receptor and recognition memory: possible modulation of its behavioral effects by the nitrergic system. Neuroscience, 2003, 118, 1121-1127.	1.1	47
43	Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity. European Journal of Endocrinology, 2003, 148, 237-243.	1.9	10
44	GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide. Journal of Endocrinology, 2002, 174, 387-394.	1.2	13
45	The non-NMDA receptor antagonist NBQX does not affect rats performance in the object recognition task. Pharmacological Research, 2002, 45, 43-46.	3.1	15
46	GH-related and extra-endocrine actions of GH secretagogues in aging. Neurobiology of Aging, 2002, 23, 907-919.	1.5	24
47	Effects of the nitric oxide donor molsidomine on different memory components as assessed in the object-recognition task in the rat. Psychopharmacology, 2002, 162, 239-245.	1.5	40
48	Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide. European Journal of Endocrinology, 2001, 145, 635-644.	1.9	14
49	Contrasting effects of nitric oxide on food intake and GH secretion stimulated by a GH-releasing peptide. European Journal of Endocrinology, 2001, 144, 155-162.	1.9	18
50	Somatostatin Infusion Withdrawal: Studies in Normal Children and in Children with Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4426-4430.	1.8	18
51	Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. European Journal of Endocrinology, 1999, 141, 313-320.	1.9	12
52	Nitric oxide modulation of the growth hormone—releasing activity of hexarelin in young and old dogs. Metabolism: Clinical and Experimental, 1999, 48, 176-182.	1.5	8
53	Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine. Journal of Endocrinology, 1998, 156, 341-348.	1.2	15
54	Unexpected Activation of Pituitary-Adrenal Axis in Healthy Young and Elderly Subjects during Somatostatin Infusion. Neuroendocrinology, 1998, 68, 123-128.	1.2	10

#	Article	IF	CITATIONS
55	Function of the GH/IGF-1 Axis in Healthy Middle-Aged Male Runners. Neuroendocrinology, 1996, 63, 498-503.	1.2	18
56	Somatostatin Withdrawal as Generator of Pulsatile GH Release in the Dog: A Possible Tool to Evaluate the Endogenous GHRH Tone?. Neuroendocrinology, 1996, 63, 481-488.	1.2	27
57	Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs. Peptides, 1995, 16, 81-86.	1.2	26
58	Growth Hormone-Releasing Hexapeptide Is a Potent Stimulator of Growth Hormone Gene Expression and Release in the Growth Hormone—Releasing Hormone—Deprived Infant Rat. Pediatric Research, 1994, 36, 169-174.	1.1	35
59	Somatotropic Dysfunction in Growth Hormone-Releasing Hormone-Deprived Neonatal Rats: Effect of Growth Hormone Replacement Therapy. Pediatric Research, 1994, 36, 315-322.	1.1	13
60	Neuroendocrine aging: Its impact on somatotrophic function. Neurochemistry International, 1994, 25, 5-10.	1.9	10
61	Eptastigmine augments basal and CHRH-stimulated growth hormone release in young and old dogs. Life Sciences, 1993, 53, 389-395.	2.0	3
62	Combined Administration of Growth-Hormone-Releasing Hormone and Clonidine Restores Defective Growth Hormone Secretion in Old Dogs. Neuroendocrinology, 1993, 57, 432-438.	1.2	21
63	Long-Term Failure of Compensatory Growth in Rats following Acute Neonatal Passive Immunization against Growth Hormone-Releasing Hormone. Neuroendocrinology, 1992, 56, 509-515.	1.2	15
64	Effect of Enhancement of Cholinergic Tone on the Growth Hormone Response to Acute Hyperglycaemia or Thyrotropin-Releasing Hormone in Dogs. Journal of Neuroendocrinology, 1992, 4, 63-66.	1.2	1
65	Studies of Growth Hormone Secretion in Calorically Restricted Dogs: Effect of Cholinergic Agonists and Antagonists, Glucose and Thyrotropin-Releasing Hormone. Neuroendocrinology, 1991, 53, 467-472.	1.2	23
66	Functional Interrelationships Between Adrenergic and Opioid Systems in the Neuroregulation of Growth Hormone Secretion in Infant Rats. Journal of Neuroendocrinology, 1991, 3, 357-361.	1.2	1
67	Down-regulation of α2-adrenoceptors involved in growth hormone control in the hypothalamus of infant rats receiving short-term clonidine administration. Developmental Brain Research, 1990, 53, 151-156.	2.1	9
68	Synergistic effect of growth hormone-releasing hormone (CHRH) and clonidine in stimulating CH release in young and old dogs. Brain Research, 1990, 537, 359-362.	1.1	30
69	Effect of cerebral hemisphere decortication on the cytotoxic activity of natural killer and natural cytotoxic lymphocytes in the mouse. Brain Research, 1990, 524, 297-302.	1.1	5
70	Age-dependent modulation by galanin of growth hormone release from rat pituitary cells in culture. Life Sciences, 1990, 47, 1861-1866.	2.0	19
71	Augmentation of Growth Hormone Secretion in Children With Constitutional Growth Delay by Short Term Clonidine Administration: A Pulse Amplitude-Modulated Phenomenon*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 426-430.	1.8	26
72	Prolonged fasting or clonidine can restore the defective growth hormone secretion in old dogs. European Journal of Endocrinology, 1989, 121, 177-184.	1.9	31

#	Article	IF	CITATIONS
73	The Effects of Galanin on Growth Hormone Secretion in Children of Normal and Short Stature1. Pediatric Research, 1989, 26, 316-319.	1.1	15
74	Neuroendocrine Control of Growth Hormone Secretion. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 87-92.	0.7	9
75	A Syndrome of Phenotypic Laron-Type Dwarfism with Normal Levels of Insulin-like Growth Factor I. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 142-142.	0.7	0
76	A Child with Phenotypic Laron Dwarfism and Normal Somatomedin Levels. New England Journal of Medicine, 1989, 320, 376-379.	13.9	22
77	Growth hormone-releasing hormone and clonidine stimulate biosynthesis of growth hormone in neonatal pituitaries. Biochemical and Biophysical Research Communications, 1986, 138, 1223-1230.	1.0	23
78	Increased Tumor Cell Multiplication after Radiofrequency Lesions in Median Hypothalamus in the Mouse and Rat. Neuroendocrinology, 1986, 42, 407-415.	1.2	7
79	Ontogeny of Growth Hormone-Releasing Factor in the Rat Hypothalamus. Neuroendocrinology, 1986, 44, 59-64.	1.2	18
80	Growth hormone releasing effect of hpGRF-40 in rats at different time intervals following ablation of the mediobasal hypothalamus. Life Sciences, 1984, 35, 1989-1995.	2.0	3
81	Presynaptic α2-adrenergic stimulation leads to growth hormone release in the dog. Life Sciences, 1984, 34, 447-454.	2.0	23
82	Autonomous /3-endorphin secretion from the pituitary neurointermediate lobe: in vivo studies. Life Sciences, 1984, 34, 1605-1611.	2.0	5
83	α2-Adrenergic stimulation enhances growth hormone secretion in the dog: A presynaptic mechanism?. Life Sciences, 1983, 32, 2785-2792.	2.0	25
84	Synthetic hpGRF 1–40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiency. Peptides, 1983, 4, 929-933.	1.2	29
85	Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog. European Journal of Endocrinology, 1983, 103, 15-20.	1.9	47